P Tech v. Arthrex: Federal Circuit Affirms Unpatentability of Deformable Fastener Patent
P Tech, LLC appealed a finding that US10376259B2 — covering a deformable fastener system — was unpatentable. The Federal Circuit affirmed in a per curiam Rule 36 judgment, leaving the patent cancelled and Arthrex’s challenge fully vindicated after 530 days of appellate proceedings.
Federal Circuit ends P Tech’s fastener patent in a Rule 36 affirmance
P Tech, LLC brought this appeal to the Court of Appeals for the Federal Circuit (Case No. 24-1389) challenging a determination that US10376259B2 — a patent directed to a deformable fastener system with relevance to orthopaedic fixation applications — was unpatentable. The appeal was filed on 26 January 2024 against Arthrex, Inc., a well-known manufacturer of orthopaedic surgical products, whose inter partes review or similar validity challenge formed the basis of the underlying proceeding.
The Federal Circuit issued a per curiam Rule 36 affirmance on 9 July 2025, adopting the lower tribunal’s unpatentability finding without a written opinion. A Rule 36 judgment means the appellate court found no reversible error sufficient to warrant written analysis — the original cancellation decision stands in full. For P Tech, this exhausts the principal appellate avenue for US10376259B2; the patent’s claims remain cancelled and unenforceable.
At 530 days, the case duration is broadly consistent with Federal Circuit appeals resolved by Rule 36 affirmance, which typically signal the panel viewed the issues as well-settled. The absence of a written opinion limits public insight into the precise legal grounds affirmed. What drove the unpatentability determination — whether anticipation, obviousness, or another ground — remains unreported, though the Rule 36 disposition suggests the lower tribunal’s reasoning was considered sound on its face.
Filing to Unpatentable in 530 days
530 days from filing to Federal Circuit judgment — consistent with typical Rule 36 affirmance timelines
Federal Circuit affirms: what the Rule 36 judgment means for both parties
Rule 36 affirmance: no reversible error, no written opinion
A Federal Circuit Rule 36 affirmance means the court adopted the lower tribunal’s judgment without writing a separate opinion. The panel — Chief Judge Moore, Judge Prost, and Judge Reyna — found no legal error that warranted published analysis. This is not a default outcome; it signals the appellate court considered the lower decision on patentability to be correct and the issues raised on appeal to lack novelty or complexity requiring elaboration.
Per curiam · Rule 36 · No written opinionUS10376259B2 remains cancelled — P Tech loses appellate challenge
For P Tech, the Rule 36 affirmance confirms that US10376259B2 is unpatentable. The patent’s claims cannot be revived through this appellate pathway. P Tech’s remaining options are extremely limited: a petition for rehearing en banc at the Federal Circuit or a certiorari petition to the Supreme Court, both of which face long odds particularly where no written opinion exists to contest on legal grounds.
Patent cancelled · Enforcement barredArthrex secures full victory — patent challenge confirmed at appellate level
Arthrex’s patentability challenge is now affirmed at the Federal Circuit level, providing maximum legal certainty. The deformable fastener technology covered by US10376259B2 can no longer be asserted against Arthrex or, arguably, third parties. This outcome strengthens Arthrex’s freedom to operate in the deformable fastener and orthopaedic fixation space without risk from this specific patent asset.
FTO confirmed · Challenge successfulCancelled patent raises FTO certainty for orthopaedic device competitors
With US10376259B2 cancelled and the cancellation affirmed, competitors in the deformable fastener and orthopaedic fixation market can treat this patent as a cleared obstacle. However, P Tech may hold related continuation or divisional patents in the same family that remain active. Companies operating in this technology space should conduct family-level FTO analysis to confirm that the affirmance eliminates exposure across the relevant claim landscape, not just the single affirmed patent.
Orthopaedic IP · FTO cleared for US10376259Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | P Tech, LLC | Company | IP licensing entity — holder of US10376259B2 (deformable fastener system)Search in Eureka ↗ |
| Defendant | Arthrex, Inc. | Company | Arthrex, Inc. — orthopaedic surgical device manufacturer and IPR petitionerSearch in Eureka ↗ |
| Plaintiff counsel | Kathleen Markowski Petrillo | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael Henry Durbin | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael J. Hartley | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Robert M. Evans | Attorney | Counsel for P Tech, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Lewis Rice LLC | Law Firm | Representing P Tech, LLCSearch in Eureka ↗ |
| Defendant counsel | Justin J. Oliver | Attorney | Counsel for Arthrex, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan S. Woodworth | Attorney | Counsel for Arthrex, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert E. Bugg Partner | Attorney | Counsel for Arthrex, Inc.Search in Eureka ↗ |
| Defendant law firm | Venable LLP | Law Firm | Representing Arthrex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s per curiam order affirms the unpatentability finding under Rule 36, issuing no written opinion. This is legally significant: Rule 36 judgments carry the same precedential weight as to the parties but provide no citable legal reasoning for future cases. The standard of review on appeal for patentability determinations from the USPTO is substantial evidence for factual findings and de novo for legal conclusions; the panel’s decision to affirm without opinion suggests both the factual record and legal analysis below were considered sound. For P Tech, no further appellate relief is available absent extraordinary circumstances.
US10376259B2 — Deformable Fastener System for Orthopaedic Fixation
US10376259B2, filed under application number US15/726503, is directed to a deformable fastener system — a category of mechanical fixation technology with direct application in orthopaedic surgical procedures such as soft tissue attachment and bone anchoring. The patent covers the structural and functional characteristics of fasteners designed to deform upon deployment, enabling secure tissue or bone fixation. This class of technology is commercially significant in rotator cuff repair, ACL reconstruction, and related minimally invasive orthopaedic procedures.
The patent’s commercial relevance stems from Arthrex’s dominant position in the orthopaedic fixation market, where deformable anchor and fastener designs are core product features. Arthrex’s decision to pursue a patentability challenge — and succeed through the Federal Circuit — suggests the claims of US10376259B2 were seen as a meaningful competitive threat. For other device manufacturers operating in this space, the cancellation removes one assertion risk but highlights that P Tech and similar NPEs may hold broader portfolios targeting fixation technology.
Should you run an FTO against US10376259B2 and its patent family?
Any company designing, manufacturing, or commercialising deformable fastener systems or orthopaedic bone anchor products should note that while US10376259B2 has been cancelled, P Tech’s broader portfolio may include continuation or divisional patents with overlapping claim scope. A freedom-to-operate analysis limited to the affirmed patent alone is insufficient — the priority chain rooted in application US15/726503 should be fully mapped before clearing product launches in the surgical fixation space.
PatSnap Eureka’s FTO Search Agent can rapidly identify all patents sharing the priority chain of US10376259B2, flag active family members, and surface prior art landscapes relevant to deformable fastener claim elements. R&D and product teams can use Eureka to generate a family tree, monitor for newly filed continuations, and benchmark claim scope against competitor patents — reducing the time to FTO clearance and strengthening design-around confidence before market entry.
Run a freedom-to-operate analysis on US10376259B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals: orthopaedic device patentability challenges
Cases involving Federal Circuit Rule 36 affirmances in orthopaedic fixation and surgical device patent validity disputes — related technology and procedural posture.
What this case signals for the orthopaedic device IP landscape
A Rule 36 affirmance at the Federal Circuit is a decisive endpoint — here is what it means for IP strategy in surgical fixation technology.
Rule 36 affirmances signal well-established law — harder to reverse on remand
When the Federal Circuit issues a Rule 36 judgment, it typically indicates the panel viewed the lower tribunal’s analysis as unambiguous. For patent challengers, this is the most efficient possible outcome. For patent holders, it signals that the quality of claim drafting and prosecution history are critical — appeals with weak records rarely generate written opinions and cannot easily leverage appellate reversal.
Orthopaedic fixation patents face heightened IPR scrutiny post-affirmance
This outcome is consistent with a broader pattern of validity challenges succeeding against mechanical fastening patents in the orthopaedic space. Companies holding similar deformable fastener or bone anchor IP should proactively audit claim scope and prior art exposure. The affirmance here raises the evidentiary baseline that challengers can point to in future IPR petitions targeting related technology.
P v Arthrex — key questions answered
The Federal Circuit affirmed the unpatentability of US10376259B2 in a per curiam Rule 36 judgment on 9 July 2025. The panel — Chief Judge Moore, Judge Prost, and Judge Reyna — found no reversible error in the lower tribunal’s cancellation decision. No written opinion was issued, meaning the affirmance provides no citable legal reasoning but is fully binding on the parties.
A Rule 36 affirmance allows the Federal Circuit to affirm a lower tribunal’s decision without issuing a written opinion, typically when the panel finds the issues well-settled or the lower decision clearly correct. For a patent holder like P Tech, it is a decisive adverse outcome: the patent remains cancelled, no written grounds are available to contest on further appeal, and the pathway to reinstatement is extremely narrow — limited to en banc rehearing or Supreme Court certiorari.
No. The Federal Circuit’s affirmance of the unpatentability finding means US10376259B2’s claims are cancelled and no longer enforceable. P Tech cannot assert this patent against Arthrex or any other party. However, related patents in the same family — continuations or divisionals sharing the US15/726503 priority chain — may still be active and should be separately evaluated for enforceability and FTO purposes.
The Federal Circuit typically issues Rule 36 judgments where the panel finds no legal error in the lower decision and the issues raised on appeal do not require elaboration. While the specific reasons are not public, the per curiam disposition suggests the patentability arguments raised by P Tech were not viewed as presenting novel or complex questions of law. This is common in IPR appeals where the evidentiary record and legal standards are well-established.
Companies operating in the deformable fastener or orthopaedic fixation space should treat this cancellation as partial — not complete — clearance. A full FTO analysis should map all patents in the P Tech portfolio sharing the US15/726503 priority chain, including any active continuations or divisional applications. The affirmance clears US10376259B2 specifically, but related claims covering similar technology may still present assertion risk from P Tech or successor rights holders.
PatSnap Eureka searches patents and litigation data to answer instantly.